Want to see DE:SBS full AI Analyst Report?

STRATEC Biomedical (SBS) Price & Analysis

6 Followers

SBS Stock Chart & Stats

€19.70

€0.28(1.42%)

At close: Jul 27 4:00 PM EDT

€19.70

€0.28(1.42%)

Day’s Range― - ―

52-Week Range€16.30 - €33.10

Previous CloseN/A

Volume3.37K

Average Volume (3M)15.55K

Market Cap

€237.28M

Enterprise Value€301.10

Total Cash (Recent Filing)€23.74M

Total Debt (Recent Filing)€116.97M

Price to Earnings (P/E)―

Beta1.47

Next Earnings

Aug 14, 2026

EPS Estimate

0.19

Next Dividend Ex-DateN/A

Dividend Yield3.07%

Share Statistics

EPS (TTM)-0.27

Shares Outstanding12,157,841

10 Day Avg. Volume11,323

30 Day Avg. Volume15,548

Financial Highlights & Ratios

PEG Ratio11.11

Price to Book (P/B)1.15

Price to Sales (P/S)1.09

P/FCF Ratio-28.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€28.00

Price Target Upside42.13% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)1.39

Revenue Forecast (FY)€263.66M

Bulls Say, Bears Say

Bulls Say

OEM/ODM Partnership ModelSTRATEC's OEM/ODM model creates durable revenue lines: upfront development fees, recurring series production, and lifecycle aftermarket/consumables. Long-term contracts and integration into partner platforms support predictable production ramps and recurring revenue as partners scale their installed base.

Supportive Balance Sheet & Lower LeverageA sizeable equity base and materially reduced reported leverage in the TTM period give STRATEC financial flexibility to absorb near-term earnings weakness, fund targeted capex, and manage elevated inventory without immediate refinancing pressure, supporting long-term operational stability.

Rebound In Operating And Free Cash FlowRecent positive operating and free cash flow, including Q1 cash strength, improves self-funding capacity for R&D and manufacturing investments. Durable cash generation reduces reliance on external financing and helps the company execute medium-term growth and margin-improvement plans despite volatile earnings.

Bears Say

Multi-year Revenue DeclineSustained top-line erosion and declining gross/operating margins indicate structural demand or mix issues. Persistent revenue contraction undermines scale economics for instrument manufacturing, pressures margins and ROE, and makes hitting medium-term growth and profit targets more challenging without clear order recoveries.

Elevated Inventory And Obsolescence RiskPersistently high inventory ties up capital, increases carrying costs, and raises obsolescence risk in fast-evolving diagnostics. Reducing stock to normal levels may compress cash if sales fail to materialize, and legacy/last-time-buy exposure could force write-offs, harming margins and returns over the medium term.

Consumables Order Visibility RiskHigh-margin consumables are key to long-run profitability. Weakness or timing shifts in consumables ordering reduces recurring revenue and gross margin sustainability. If customers delay purchases or shift forecasting practices, STRATEC's margin recovery and free cash flow resilience could be materially delayed.

STRATEC Biomedical News

STRATEC Biomedical Balances Weak Q1 With Firm Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

STRATEC Biomedical Balances Q1 Setback With Solid Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

0RAR Upcoming Earnings Report: What to Expect?

STRATEC Biomedical (0RAR) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street analysts...

4M ago

STRATEC Biomedical’s Earnings Call: Mixed Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q3 earnings call. Read on for the main highlights of the call....

9M ago

STRATEC Biomedical (0RAR) Unveils Dividend Details for Q3: Mark Your Calendar!

STRATEC Biomedical (LSE: 0RAR) has declared, under its dividend policy, a yearly cash dividend in the amount of...

1y ago

0RAR Earnings this Week: How Will it Perform?

STRATEC Biomedical (0RAR) is scheduled to report 3rd quarter earnings on 10/25/2024, before the market opens. Regarding Q3...

2y ago

SBS FAQ

What was STRATEC Biomedical AG’s price range in the past 12 months?

STRATEC Biomedical AG lowest stock price was €16.30 and its highest was €33.10 in the past 12 months.

What is STRATEC Biomedical AG’s market cap?

STRATEC Biomedical AG’s market cap is €237.28M.

When is STRATEC Biomedical AG’s upcoming earnings report date?

STRATEC Biomedical AG’s upcoming earnings report date is Aug 14, 2026 which is in 11 days.

How were STRATEC Biomedical AG’s earnings last quarter?

Currently, no data Available

Is STRATEC Biomedical AG overvalued?

According to Wall Street analysts STRATEC Biomedical AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does STRATEC Biomedical AG pay dividends?

STRATEC Biomedical AG pays a Annually dividend of €0.6 which represents an annual dividend yield of 3.07%. See more information on STRATEC Biomedical AG dividends here

What is STRATEC Biomedical AG’s EPS estimate?

STRATEC Biomedical AG’s EPS estimate is 0.19.

How many shares outstanding does STRATEC Biomedical AG have?

STRATEC Biomedical AG has 12,157,841 shares outstanding.

What happened to STRATEC Biomedical AG’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of STRATEC Biomedical AG?

Currently, no hedge funds are holding shares in DE:SBS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

STRATEC Biomedical Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
€28.00 (42.13% Upside)

Technicals

Top Smart Score Stocks >

Company Description

STRATEC Biomedical AG

Established in 1979 and headquartered in Birkenfeld, Germany, Stratec SE (previously known as STRATEC Biomedical AG until its name change in December 2018) specializes in the development and manufacturing of cutting-edge automation and instrumentation systems. The company caters to the in-vitro diagnostics and life sciences sectors, operating across Germany, the European Union, and globally. Its business is divided into three primary segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on designing and fabricating automated analytical systems, along with necessary spare parts and supplies, for customers in clinical diagnostics and biotechnology. The Diatron segment provides a suite of systems, components, disposables, and assays for lower-volume hematology and clinical chemistry applications. Finally, the Smart Consumables segment is dedicated to engineering and producing intelligent consumables for the diagnostics, life sciences, and medical technology industries.

STRATEC Biomedical (SBS) Earnings & Revenues

Historic Earnings Reports

SBS Stock 12 Month Forecast

Average Price Target

€28.00

▲(42.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"€15","38":"€38","20.75":"€20.8","26.5":"€26.5","32.25":"€32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,20.75,26.5,32.25,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.52,20.864615384615384,22.209230769230768,23.553846153846152,24.89846153846154,26.24307692307692,27.587692307692308,28.932307692307692,30.276923076923076,31.62153846153846,32.966153846153844,34.31076923076923,35.65538461538462,{"y":37,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.52,20.17230769230769,20.824615384615385,21.476923076923075,22.12923076923077,22.78153846153846,23.433846153846154,24.086153846153845,24.73846153846154,25.39076923076923,26.043076923076924,26.695384615384615,27.347692307692306,{"y":28,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.52,19.633846153846154,19.747692307692308,19.861538461538462,19.975384615384616,20.08923076923077,20.203076923076924,20.316923076923075,20.43076923076923,20.544615384615383,20.658461538461538,20.77230769230769,20.886153846153846,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.856,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.518,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.336,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.714,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.941,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.265,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.96,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.915,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.012,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.528,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >